Ten months ago, when MDS Proteomics held an opening ceremony at its flagship facility in Toronto, a panel of scientists and managers trumpeted the advent of a new age in drug discovery that proteomics would make manifest. It was a giddy time for the subsidiary of Canadian health care giant MDS, which had sunk millions into assembling an impressive suite of mass spectrometry, computational prowess, and scientific expertise.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.